-inc-logo.jpg?v=20240515130629 "Definium Therapeutics, Inc. logo"){kind=logo}
Needham & Company LLC reiterated their buy rating on shares of Definium Therapeutics (NASDAQ:DFTX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $66.00 target price on the stock.
DFTX has been the topic of several other reports. Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Bank of America initiated coverage on Definium Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price objective on the stock. Robert W. Baird boosted their target price on Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Oppenheimer reaffirmed an “outperform” rating and set a $70.00 target price on shares of Definium Therapeutics in a research report on Wednesday, August 12th. Finally, Maxim Group set a $55.00 price target on Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics has a consensus rating of “Buy” and an average target price of $64.88.
View Our Latest Stock Analysis on Definium Therapeutics
Definium Therapeutics Stock Performance
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts expect that Definium Therapeutics will post -3.02 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 67,119 shares of company stock valued at $2,887,496. 2.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On Definium Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC bought a new stake in Definium Therapeutics in the 4th quarter valued at $66,950,000. Wellington Management Group LLP acquired a new stake in shares of Definium Therapeutics during the 2nd quarter valued at about $138,755,000. Seven Grand Managers LLC bought a new stake in Definium Therapeutics in the fourth quarter valued at about $3,013,000. Seven Fleet Capital Management LP acquired a new position in Definium Therapeutics in the second quarter worth about $6,992,000. Finally, UBS Group AG lifted its stake in Definium Therapeutics by 23.9% during the fourth quarter. UBS Group AG now owns 683,802 shares of the company’s stock worth $9,156,000 after purchasing an additional 131,993 shares during the period. Institutional investors own 27.91% of the company’s stock.
Definium Therapeutics News Summary
Here are the key news stories impacting Definium Therapeutics this week:
- Positive Sentiment: Definium reported a second successful Phase 3 trial for DT120 orally disintegrating tablets in generalized anxiety disorder. The treatment produced statistically significant improvements in anxiety symptoms, supporting the company’s plans to engage with the FDA and pursue a potential 2027 regulatory filing. Definium Reports Second Phase III Success
- Positive Sentiment: Robert W. Baird raised its price target for DFTX from $75 to $79 and maintained an “outperform” rating, implying substantial potential upside from the stock’s recent trading level. Baird Raises Definium Price Target
- Positive Sentiment: HC Wainwright reiterated its “buy” rating, while Needham & Company also assigned a “buy” rating. The recommendations indicate continued Wall Street confidence in Definium’s clinical and commercial prospects. HC Wainwright Reiterates Buy Rating Needham Gives Definium a Buy Rating
- Positive Sentiment: Healthcare-focused commentary described analysts as bullish on Definium and suggested the shares could trade at a premium after the Phase 3 success, with another analysis characterizing the stock as undervalued. Analysts Are Bullish on Definium Definium Still Looks Undervalued
- Negative Sentiment: Traders purchased a large volume of DFTX put options, signaling that some market participants are positioning for downside or hedging against volatility. This is a cautionary counterpoint to the predominantly bullish analyst coverage. Large Definium Put-Option Activity
About Definium Therapeutics
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Stories
- Five stocks we like better than Definium Therapeutics
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
